To the Editor: Valve stenosis and regurgitation can lead to a series of symptoms, including chest distress and dyspnea. Valve replacement is an effective surgical procedure that improves patients' quality of life and life span and has played an increasingly important role in treating mitral valve diseases. Previous studies have reported different risk factors and independent predictors of increased mortality in patients with mitral valve replacement (MVR) and/or aortic valve replacement (AVR).\[[@ref1][@ref2][@ref3]\] This study retrospectively reviewed data on patients undergoing valve surgery to determine the risk factors and predictors of short-term mortality in this patient population.

The data of 1254 patients who underwent valve surgery from January 2014 to December 2015 in the First Affiliated Hospital of Zhejiang University were reviewed. Patients with concomitant coronary artery bypass grafting (CABG) were included, while those with concomitant aortic dissection surgery or complex congenital heart disease surgery were excluded. Clinical, echocardiographic, and surgical data from the electronic medical records were reviewed. Short-term mortality was defined as all-cause death during or within 30 days of surgery. The patients, who underwent preoperative transthoracic echocardiography (TTE), electrocardiography (ECG), and coronary artery imaging, mostly received a coronary computed tomography angiogram (CTA) to get useful data. Patients with abnormal coronary CTA results or a high risk of coronary heart disease (CHD) required a coronary angiogram.

The 99% of the patients (1242 of 1254) included in the study underwent surgical procedures through a median sternotomy followed by a cardiopulmonary bypass with systemic hypothermia (central temperature: 28°C--32°C). Concomitant CABG was performed in 35 patients. Valve function was confirmed through TTE after they had been weaned off cardiopulmonary bypass.

Statistical analysis was performed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). Pearson\'s Chi-square tests were used to compare inhospital mortality rates between groups. All multivariate analyses were performed with *P* \< 0.05 as the limit on univariate analysis for entering or removing variables. A *P* \< 0.05 was considered statistically significant.

Among the 1254 patients who underwent valve surgery, 25 (2.0%) short-term deaths were recorded. The causes of death were cardiac failure (8 patients), multiple system failure (7 patients), cerebral infarction (4 patients), thoracic incision infection (3 patients), renal failure (2 patients), and fatal arrhythmia (1 patient). Patients' baseline characteristics are presented in [Table 1](#T1){ref-type="table"}. Patients with a New York Heart Association (NYHA)-4 experienced significantly higher postsurgery mortality (15.0% vs. 1.8%, *P* \< 0.001). Compared to nonsmoking patients, patients with a smoking history also had increased mortality (5.0% vs. 1.6%, *P* \< 0.001), as did those with a history of CHD (7.4% vs. 1.9%, *P* = 0.042). A low ejection fraction (EF) (\<50.0%, *P* \< 0.001), moderate or severe mitral regurgitation (*P* = 0.021), and tricuspid regurgitation (*P* = 0.012) discovered by ECG were all found to be risk factors for valve surgery. Patients with a history of cardiac surgery had a higher mortality rate (9.4% vs. 1.8%, *P* = 0.002), and those who underwent valve surgeries with concomitant CABG or reoperation for major bleeding or pericardial tamponade had a significantly higher rate as well (8.6% vs. 1.8%, *P* = 0.005, and 22.2% vs. 1.7%, *P* \< 0.001; respectively).

###### 

Patients' clinical characteristics and short-term mortality in this study (*N* = 1254), *n* (%)

  Items                            Number        Short-term mortality   *χ*^2^   *P*
  -------------------------------- ------------- ---------------------- -------- ---------
  Age                                                                            
   \<60 years                      690 (55.0)    12 (1.7)               0.51     0.476
   ≥60 years                       564 (45.0)    15 (2.7)                        
  Gender                                                                         
   Male                            563 (44.9)    12 (2.1)               0.10     0.753
   Female                          691 (55.1)    13 (1.9)                        
  BMI                                                                   0.01     0.940
   \<24 kg/m^2^                    844 (67.3)    17 (2.0)                        
   ≥24 kg/m^2^                     410 (32.7)    8 (2.0)                         
  NYHA-4                                                                         
   No                              1234 (98.4)   22 (1.8)               17.60    \<0.001
   Yes                             20 (1.6)      3 (15.0)                        
  Renal dysfunction                                                              
   No                              1226 (97.8)   25 (2.0)               0.58     0.445
   Yes                             28 (2.2)      0 (0.0)                         
  Diabetes                                                                       
   No                              1200 (95.7)   24 (2.0)               0.01     0.907
   Yes                             54 (4.3)      1 (1.9)                         
  Hypertension                                                                   
   No                              986 (78.6)    21 (2.1)               0.44     0.508
   Yes                             268 (21.4)    4 (1.5)                         
  Smoker                                                                         
   No                              1094 (87.2)   17 (1.6)               8.48     0.004
   Yes                             160 (12.8)    8 (5.0)                         
  Peripheral vascular disease                                                    
   No                              1221 (97.4)   25 (2.1)               0.69     0.406
   Yes                             33 (2.6)      0 (0.0)                         
  Cerebrovascular disease                                                        
   No                              1233 (98.3)   25 (2.0)               0.43     0.510
   Yes                             21 (1.7)      0 (0.0)                         
  Coronary heart disease symptom                                                 
   No                              1227 (97.9)   23 (1.9)               4.14     0.042
   Yes                             27 (2.1)      2 (7.4)                         
  Atrial fibrillation                                                            
   No                              794 (63.3)    19 (2.4)               1.77     0.184
   Yes                             460 (36.7)    6 (1.3)                         
  Ejection fraction                                                              
   ≥50%                            1169 (93.2)   17 (1.5)               25.68    \<0.001
   \<50%                           85 (6.8)      8 (9.4)                         
  Previous cardiac surgery                                                       
   No                              1222 (97.4)   22 (1.8)               9.16     0.002
   Yes                             32 (2.6)      3 (9.4)                         
  Mitral stenosis                                                                
   No                              638 (50.9)    15 (2.4)               0.85     0.357
   Yes                             616 (49.1)    10 (1.6)                        
  Mitral regurgitation                                                           
   No or mild                      780 (62.2)    10 (1.3)               5.35     0.021
   Moderate or severe              474 (37.8)    15 (3.2)                        
  Mitral valve operation                                                         
   No                              325 (25.9)    5 (1.5)                0.47     0.495
   Yes                             929 (74.1)    20 (2.2)                        
  Mitral valve replacement                                                       
   No                              108 (11.6)    0 (0.0)                2.69     0.101
   Yes                             821 (88.4)    20 (2.4)                        
  Mitral valve repair                                                            
   No                              821 (88.4)    20 (2.4)               2.69     0.101
   Yes                             108 (11.6)    0 (0.0)                         
  Aortic stenosis                                                                
   No                              868 (69.2)    16 (1.8)               0.33     0.568
   Yes                             386 (30.8)    9 (2.3)                         
  Aortic regurgitation                                                           
   No or mild                      797 (63.6)    17 (2.1)               0.22     0.641
   Moderate or severe              457 (36.4)    8 (1.8)                         
  Aortic valve operation                                                         
   No                              581 (46.3)    13 (2.2)               0.33     0.566
   Yes                             673 (53.7)    12 (1.9)                        
  Tricuspid stenosis                                                             
   No                              1253 (99.9)   25 (2.0)               0.02     0.887
   Yes                             1 (0.1)       0 (0.0)                         
  Tricuspid regurgitation                                                        
   No or mild                      1072 (85.5)   17 (1.6)               6.29     0.012
   Moderate or severe              182 (14.5)    8 (4.4)                         
  Tricuspid repair                                                               
   No                              996 (79.4)    20 (2.0)               0.01     0.943
   Yes                             258 (20.6)    5 (1.9)                         
  Nonelective surgery                                                            
   No                              1246 (99.4)   25 (2.0)               0.16     0.686
   Yes                             8 (0.6)       0 (0.0)                         
  Biological valve                                                               
   No                              978 (78.0)    19 (1.9)               0.06     0.808
   Yes                             276 (22.0)    6 (2.2)                         
  Mechanical valve                                                               
   No                              397 (31.7)    6 (1.5)                0.69     0.406
   Yes                             857 (68.3)    19 (2.2)                        
  Concomitant CABG                                                               
   No                              1219 (97.2)   22 (1.8)               7.97     0.005
   Yes                             35 (2.8)      3 (8.6)                         
  Reoperation                                                                    
   No                              1236 (98.6)   21 (1.7)               38.25    \<0.001
   Yes                             18 (1.4)      4 (22.2)                        

CABG: Coronary artery bypass grafting; NYHA: New York Heart Association.

Based on univariate analysis, multivariate logistic regression analyses of inhospital mortality showing NYHA-4 (odds ratio \[*OR*\]: 8.7, 95% confidence interval \[*CI*\]: 2.1--36.2, *P* = 0.003), smoking history (*OR*: 3.7, 95% *CI*: 1.5--9.3, *P* = 0.005), poor EF (*OR*: 5.4, 95% *CI*: 2.2--13.5, *P* \< 0.001), previous cardiac surgery (*OR*: 10.9, 95% *CI*: 2.6--46.2, *P* = 0.001), moderate or severe tricuspid regurgitation (*OR*: 3.2, 95% *CI*: 1.3--8.1, *P* = 0.012), and concomitant CABG (*OR*: 5.0, 95% *CI*: 1.3--19.2, *P* = 0.020) to be potential risk factors for short-term mortality \[[Table 2](#T2){ref-type="table"}\].

###### 

Predictors of inhospital mortality by univariate analysis and multivariate logistic regression analysis

  Variables                  Univariate analysis   Multivariate analysis                                      
  -------------------------- --------------------- ----------------------- --------- ----- ------ ----------- ---------
  NYHA-4                     9.7                   2.7--35.6               0.001     2.2   8.7    2.1--36.2   0.003
  Smoking history            3.3                   1.4--7.9                0.006     1.3   3.7    1.5--9.3    0.005
  CHD symptoms               4.2                   0.9--18.7               0.061                              
  EF \<50%                   5.4                   2.3--12.9               \<0.001   1.7   5.5    2.2--13.5   \<0.001
  Previous cardiac surgery   9.7                   2.7--35.6               0.001     2.4   10.9   2.6--46.2   0.001
  Mitral regurgitation       2.5                   1.1--5.6                0.028                              
  Tricuspid regurgitation    2.9                   1.2--6.7                0.016     1.2   3.2    1.3--8.1    0.012
  Concomitant CABG           4.9                   1.4--17.3               0.013     1.6   5.0    1.3--19.2   0.020

CABG: Coronary artery bypass grafting; *CI*: Confidence interval; CHD: Coronary heart disease; EF: Ejection fraction; NYHA: New York Heart Association; *OR*: Odds ratio.

Over 200,000 patients suffer from chest distress, dyspnea, and poor mobility caused by morphological defects of the heart valves in China every year and are recommended for valve surgery. AVR and MVR are the classic treatments for most patients with heart valve disease (HVD), but the ratio of mitral valvuloplasty has been increased in recent years. This study directly evaluated the pre- and postoperative risk factors for short-term mortality in Chinese patients who underwent valve surgery. We thought that these identified risk factors are very important due to the particular characteristics of the East Asian population, such as a different etiology from the Western population and less stringent postsurgery anticoagulation requirements. This study included a total of 1254 patients who underwent valve surgery in single center. The unadjusted short-term mortality of this study was 2.0%. As expected, preoperative NYHA-4, smoking, poor EF, previous cardiac surgery, moderate or severe tricuspid regurgitation, and concomitant CABG were independent risk factors for short-term mortality. Previous research has reported the similar findings.\[[@ref1][@ref2]\] In addition, 18 patients who received reoperation owing to major bleeding or pericardial tamponade accounted for 22.2% of the mortality in our sample.

Several studies have shown that age was an independent risk factor for short-term mortality.\[[@ref1][@ref2]\] However, the results of this study suggested no strong correlation between age and short-term mortality. Only 11.5% of the patients in this study were over 70 years old, in which there were patients with NYHA-4 and just one with an EF \<30% (data not shown). Due to the low proportion of old-age patients in this study, it was insufficient to conclude that older patients who underwent valve surgery were at greater risk than the younger patients.

With regard to the causes of short-term mortality, only 24.0% of the deaths in this study (6 out of 25) were related to atrial fibrillation, which was found in 36.7% of the patients. These patients with atrial fibrillation accounted for only 1.6% of the deaths following value surgery. Hence, there was insufficient evidence to identify atrial fibrillation as a risk factor for increased mortality. As a result, in concordance with other research,\[[@ref4]\] we concluded that atrial fibrillation was not a risk factor for increased mortality, although several studies have cited it as a postvalue surgery risk factor, which influenced perioperative mortality.\[[@ref2]\]

Previous studies have developed preoperative risk assessment models for valve operations, mostly were intended for populations in the USA.\[[@ref2][@ref5]\] These models might not be well suitable for patients in China or Asia because of the differences in demographic characteristics. In this study, such factors such as age, gender, renal dysfunction, diabetes, hypertension, and atrial fibrillation did not make a statistically significant contribution to short-term mortality following valve surgery.

The study had several limitations that should be noticed. First of all, the sample size was not large enough to generalize all obtained variables. Between-factor crosstalk also cannot be ruled out. Second, our data were extracted from a single center, which may not represent the actual short-term mortality in the Zhejiang region. Finally, the variables included in this study were not exhaustive of all variables that potentially affect mortality.

In conclusion, this study statistically analyzed NYHA-4, smoking history, poor EF, previous cardiac surgery, moderate or severe tricuspid regurgitation, and concomitant CABG to be the independent risk factors for short-term mortality in patients who had undergone valve surgery in Zhejiang of China. It helps cardiac surgeons to evaluate the short-term mortality of valve surgeries due to the special demographic characteristics of HVD patients here.
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